Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer and Immunoblot - Test currently unavailable

Sunquest Code:PURKAR  
Order Instructions:Test currently unavailable.
Synonyms:YO Antibody; Purkinje Cells
Methodology:Indirect fluorescent antibody/Immunoblot
CPT Code:86255, 83516, 86256
Turnaround Time:Specimens are sent to reference laboratory Mon-Sat; results are reported in 1-9 days.

This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Collection Instructions

Optimal Volume:2 mL
Minimum\Peds Volume:1.2 mL
Container:Red or gold (gel) (Red (no gel))
Causes for Rejection:Lipemic, hemolyzed, contaminated or heat-inactivated specimens.

Processing and Shipping

Specimen Processing:Separate serum from cells ASAP. Aliquot 1 mL, 0.5 mL minimum. Store in refrigerator.
Shipping Instructions:Ship at refrigerated temperature.
Test Performed at or Referral Lab Lab Sendouts  (ARUP)
Referral Lab number:59444 (PCCA R)


Reference Range:

If Purkinje cell screen is 1:10, then a titer and immunoblot will be added.

Purkinje Cell Cytoplasmic Antibody (PCCA or PCA-1) Screen

Less than 1:10

Purkinje Cell Cytoplasmic Antibody (PCCA or PCA-1) Titer

Less than 1:10

Purkinje Cell Cytoplasmic Antibody (PCCA or PCA-1) Immunoblot




Use:There is a strong association among paraneoplastic syndromes, anti-neuronal antibody specifications and the associated tumor type. However, in a minority of patients with paraneoplastic syndrome with anti-neuronal antibodies, no tumor may be found. Certain patients with paraneoplastic syndromes may not have detectable levels (by IFA) of anti-neuronal antibodies. Most cases that develop paraneoplastic cerebellar degeneration (PCD) in association with Hodgkin's disease, non-SCLC, gastrointestinal carcinomas do not have demonstrable anti-Yo antibodies. There also exist anti-Yo negative but atypical anti-Purkinje cell cytoplasm autoantibodies (atypical APCA's). Such antibodies can occur in association with Hodgkin's disease, adenocarcinoma of the lung, colon or prostate. 5-6% of patients with ovarian cancer have circulating anti-Yo or anti-Ri antibodies in the absence of any paraneoplastic neurological syndromes.

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 1432"